Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE: CRL) announced the launch of Apollo™ for CRADL®, a secure cloud-based platform enhancing their vivarium rental services. The platform streamlines research initiation by providing a centralized dashboard connecting clients to online training, research models ordering, and study support services.

Apollo serves as the technology stack driving Charles River's digital transformation, offering expanded client access across their portfolio through multiple integrations:

• Apollo for CRADL: Streamlines administrative tasks for vivarium rental solutions
• Apollo for Safety Assessment: Provides real-time access to data visualization and program planning
• Apollo for Biologics: Centralizes sample submission and tracking
• Apollo for Discovery: Enables instant oncology study price estimates
• Apollo for Logica®: Delivers real-time updates for AI-powered small molecule programs
• Research Models Online Ordering System: Offers interactive catalog with real-time inventory

Charles River Laboratories (NYSE: CRL) and Akron Bio announced the integration of Akron's Closed System Solutions (CSS)™ line of liquid cytokines into Charles River's Cell Therapy Flex Platform for Process Development. This integration aims to enhance closed system processing, streamline operations, and improve process robustness.

The Cell Therapy Flex Platform, designed as an off-the-shelf solution for Cell Therapy Process Development, now incorporates Akron's CGMP liquid cytokines, including rHu IL-2, IL-7, IL-15, and IL-21. These cytokines are available in single-use bags with weldable tubing, maintaining stability at 2-8°C and enabling rapid, aseptic media formulation while minimizing operator error.

This collaboration enhances manufacturing efficiency by decreasing labor requirements and improving process robustness for CAR-T and TCR-T cell therapies development.

Charles River Laboratories (NYSE: CRL) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). The presentation will feature management's overview of the company's strategic focus, business developments, and recent trends.

Investors and interested parties can access a live webcast of the presentation through a link that will be available on the Investor Relations section of Charles River's website at ir.criver.com. A replay of the webcast will be accessible through the same website following the presentation and will remain available for a minimum of two weeks.

Deciphex has secured $32.3 million in Series C funding led by Molten Ventures, with participation from multiple investors including Charles River Laboratories (NYSE: CRL). The funding aims to address the global pathology shortage, where over 70% of healthcare decisions require pathology investigation amid declining pathologist numbers.

The company's AI-powered platforms, Diagnexia and Patholytix, enable pathologists to work up to 40% faster while maintaining diagnostic accuracy. The funding will support global expansion across the US, UK, EU, Canada, and Japan, enhance platform capabilities, accelerate AI foundational model development, strengthen partnerships with industry leaders like Novartis and Charles River Laboratories, and expand services to pharmaceutical, biotech, and CRO clients.

Charles River Laboratories (NYSE: CRL) has launched the Charles River Incubator Program (CIP), aimed at supporting early-stage biotechnology companies in the discovery, development, and manufacturing of advanced therapies. Through its Global Innovation Center of Excellence, CIP offers knowledge, connectivity, and priority access to Charles River's extensive portfolio. This initiative builds on the success of the Cell and Gene Therapy Accelerator Program (CAP), designed to assist companies 18-24 months from Investigational New Drug (IND) or Clinical Trial Application (CTA) submission. CIP targets companies 24+ months from IND or CTA submission, providing regulatory and quality expertise, personnel training, and access to laboratory space and equipment. The Global Innovation Center of Excellence integrates a team of scientific, regulatory, and manufacturing experts to foster innovation and support thousands of IND and CTA submissions. The next cohort will be shortlisted at the Cell and Gene Therapy Summit on March 4, 2025, in San Francisco, CA.

Charles River Laboratories (NYSE: CRL) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. During the event, the management will discuss strategic focus, business developments, and recent trends. A live webcast of the presentation will be accessible via the Investor Relations section of the Charles River website at ir.criver.com. The webcast replay will be available on the same site for at least two weeks post-presentation.

Charles River Laboratories (NYSE: CRL) has announced its upcoming presentations at two major healthcare conferences. The company will present at the UBS Global Healthcare Conference on November 12th at 10:15 a.m. PT and the Jefferies London Healthcare Conference on November 20th at 2:00 p.m. GMT.

Management will discuss the company's strategic focus, business developments, and recent trends. Both presentations will be available via live webcast through the Investor Relations section of Charles River's website, with replays accessible for at least two weeks afterward.

Charles River Laboratories (NYSE: CRL) reported Q3 2024 revenue of $1.01 billion, down 1.6% from $1.03 billion in Q3 2023, with a 2.7% organic decline. The company's GAAP operating margin decreased to 11.6% from 14.8%, while non-GAAP operating margin fell to 19.9% from 20.5%. GAAP earnings per share dropped 21.3% to $1.33, and non-GAAP EPS decreased 4.8% to $2.59. The decline was primarily driven by lower revenue and higher restructuring costs, despite improvements in all three business segments' operating margins.

Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Retrogenix® Non-Human Protein Library, a first-in-class in vitro library designed to assess off-target binding and de-risk in vivo studies. This innovative tool helps biopharmaceutical clients evaluate how therapeutics interact with non-human protein targets, providing early insights without the lead time and expense of ex vivo or in vivo studies.

The library builds on the established Retrogenix® platform, which offers the industry's largest library of human proteins for screening. By confirming whether potential off-targets are conserved across species, the new non-human library enhances the interpretability of in vivo results and aids in selecting appropriate models for safety studies. This approach aligns with the 3Rs principles (Reduction, Refinement, Replacement) in animal research and supports Charles River's Alternative Methods Advancement Project (AMAP).